Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-599-9 | CAS number: 7647-15-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
Rats received KBr in food for 104 weeks in a testing regime approximating OECD guideline 453.
No detrimental changes were seen in the clinical signs, mortality, food and water consumption, ophthalmoscopic examination, haematology, clinical chemistry, urinalysis or organ weights of the treated animals. There is no evidence for potential carcinogenicity.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1990
- Reliability:
- 2 (reliable with restrictions)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan Inc (Kangawa Japan)
- Age at study initiation: 4 week old
- Weight at study initiation: Not specified
- Fasting period before study: Not specified
- Housing: Housed five to a wire-mesh stainless-steel cage in a barrier-sustained room.
- Diet (e.g. ad libitum): yes
- Water (e.g. ad libitum): yes
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): room temperature: 23-25 °C
- Humidity (%): 45-65%
- Air changes (per hr): 12 air changes/hour
- Photoperiod (hrs dark / hrs light): 12 hours light/dark
The environmental temperature and humidity were within the specified range - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): monthly
- Mixing appropriate amounts with (Type of food): Basal pellet diet (Oriental MF: Oriental Yeast Co, Ldt, Tokypo, Japan)
- Storage temperature of food: 23°C
VEHICLE
- Justification for use and choice of vehicle (if other than water): Not specified
- Concentration in vehicle: 500 ppm for KBr.
- Amount of vehicle (if gavage):
- Lot/batch no. (if required): Not specified
- Purity: Not specified - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Confirmed to be stable.
- Duration of treatment / exposure:
- 104 weeks
- Frequency of treatment:
- Daily
- Post exposure period:
- N/A
- Remarks:
- Doses / Concentrations:
500 ppm
Basis:
nominal in diet
KBr - No. of animals per sex per dose:
- 60 rats/sex/dose
- Control animals:
- yes, plain diet
- Details on study design:
- The rats were randomly allocated to 5 groups: 3 test material groups ( 500, 200, 80) test substance group KBr (500) and basal diet, each consisting of 60 males and 60 females. The randomization was continued until the body-weight ditribution was approximatively the same betweens groups. The KBr groups was fed ad lib the diet containing 500 ppm inorganic bromide prepared with the addition of potassium bromide to the basal diet. The basal diet group was given basal diet alone. Water was given ad lib.
- Positive control:
- No
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: Once a week for the first 13 week and once every 4 week thereafter.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Once a week for the first 13 week and once every 4 week thereafter. The total bromine intake in rats (mg /kg b.w./day) was calculated from their food consumption and body weights.
FOOD EFFICIENCY:
- Food conversion efficiency was calculated from the ratio of body-weight gain to food consumption.
ORGAN WEIGHTS:
The following organs were weighed and the organ/body weight ratios (relative organ weights) were calculated: brain pituitary, thyroids, with parathyroids, , heart, liver, spleen,kidneys, adrenals, testes and ovaries.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: Once a week for the first 13 week and once every 4 week thereafter.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Before the start of the study and at week 104, 10 males and 10 females from the control (basal diet) group and the groups given 500 ppm total bromine were subjected to ophtalmological examination.
HAEMATOLOGY: Yes
- Blood samples were collected using heperinized syringes from the posterior vena cava of ten males and ten females from each group that were killed by exsanguination under ether anaesthesia after 52 week and 104 week.
- Each of the sample was poured into a cup with ethylenediamine tetraacetic acid and haematocrit, haemoglobin concentration, mean corpuscular haemoglobin, mean corpuscular volume, mean corpuscular haemoglobin, concentration and erythrocyte, platelet and leucocyte counts were determined.Differencial leucocyte counts were calculated by multiplying the leucocyte count by the percentage of each leucocyte determined on blood smears stained with May-Grünwald and Giemsa stains.
Plasma from the blood samples was analysed by conventional methods for total protein, albumin, globulin, albumin/globulin ratio, alkaline phosphatase, blood, urea nitrogen, creatinine, glucose, total cholesterol, glutamic-pyruvic transaminase, glutamine-oxoloatic transaminase, 7-glutamyl transpeptidase, total bilirubin, calcium, phosphorus, sodium, potassium and chlorine.
URINALYSIS: Yes
- Urine was collected from 10 males and 10 females in each group at week 52 and 104. Specific gravity was determined using a refractomer on fresh urine obtained by pressing the lumbodorsal portion of the rats. Semi-quantitative observations of pH protein, glucose, ketones, occult blood, urobilinogen and bulirubin were also carried out. Urine 24 hour volume, and sediment were then determined in urine samples that were collected from rats housed in individual urine sampling cages.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
A thorough necropsy was performed on the 10 male and 10 demale rats per group that were killed at week 52 and on all surviving rats that were killed at week 104. The following organs were weighed and the organ/body weight ratios (relative organ weights) were calculated: brain pituitary, thyroids, with parathyroids, , heart, liver, spleen,kidneys, adrenals, testes and ovaries. Samples of these organs and of the spinal cord, sicatic nerve, thymus, bone with marrow, cervical and mesenteric lymph nodes, aorta, salivary gland, oesophagus, forestomach, glandular stomach, small and large intestine, trachea lung, urinary bladder, epididymides, prostate, seminal vesicles, uterus, eyes, Harderian glands, skeletal muscle, skin, mammary glands (female) and all gross lesions are fixed in 10% neutral buffered formalin, embedded in parrafin wax, sectioned at 5 µm and stained with haemotoxylin and eosin. Detailed microscopic examinations were carried out on all of the organs mentioned above from all rats from each group.
A thorough necropsy was also performed on rats that were found dead or were killed in extremis during the study. As far as possible, the organs and tissues in this rats were preserved and examined. - Other examinations:
- No
- Statistics:
- The multiple comparison test (Dunnett’s or Scheffé’s method) was used to analyse data on body weight, food consumption, water consumption, urinalysis (specific gravity and urine volume), haematology, blood biochemistry and organ weights in order to determine the significance of the results. Mortality was evaluated by life-table analysis. The Mann-Whitney U test was applied to the urinalysis data except for those on specific gravity and urine volume. Fisher’s exact probability test was used for the analysis of data on ophthalmology and gross histopathology. The significance of the differences between the basal diet and treated groups was estimated at 5 and 1% levels of probability
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- No effects were observed on the behaviour of the rats treated with KBr.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- No effects were observed on the behaviour of the rats treated with KBr.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Higher body weights than those in the basal diet group were noted in the KBr group at weeks 1-6 (males) and at weeks 1, 10, 16, 24-36 and 44 (females).
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Higher food consumption was seen at weeks 3 and 4 (males) and at weeks 1-4 (females) of the KBr treated group. The compound intake was equivalent to 16.5 mg/kg bw/day (males) and 20.0 mg/kg bw/day (females).
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- Water consumption was statistically significantly higher in the treated group than in the control group at weeks 1-2, 7-8, 10, 13 and 24 in females).
- Ophthalmological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Several of the lesions observed in the treated and control groups were considered to be spontaneous. There was no lesion that showed a statistically significantly increased incidence.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no significant differences between groups in haematological indices.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Treated males showed a slightly increased concentration in calcium at week 52. However, this result was within the normal range seen in historical data, and there were no statistically significantly different differences between the treated and control gr
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Urinalysis revealed statistically significant increases in mean values of specific gravity and in the number of rats showing a moderate degree of urobilinogen in males of the treated group at week 52 in comparison with the control. However, these changes
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver, kidneys, adrenals, testes, ovaries, spleen, brain, heart, pituitary, thyroids with parathyroids - There were no significant changes in the absolute weights of any organ in any of the treated groups in comparison with the control group.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- No abnormal observations (not including tumour formation) were noted by the author.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- The overall incidence of prostatitis (20/60) was significantly increased in comparison with the control group (10/60). This lesion is described by the author as a focal inflammatory lesion characterised by neutrophilic infiltration into the glandular spac
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
- No effects were observed on the behaviour of the rats in group fed Kbr containing diets. The number of rats that survived to 104 week in the basal diet and KBr 500 ppm groups were respectively, 42 and 43 (males) and 39 and 40 (females). Therefore, there was no statiscally significant difference in mortality between the group fed the basal diet and those fed KBr-supplement diets.
BODY WEIGHT AND WEIGHT GAIN:
- Higher body weights than those in the basal diet were noted in KBr (500) group at week 1-6 in males and at week 1, 10, 16, 24-36 and 44 in females.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
- Higher food consumption was seen at week 3 and 4 in males at week 1-4 in females. Throughout the study, the overall mean intake of totale bromine in he KBr (500) was 16.5 mg/kg bw/day in males and 20 mg/kg bw/day in females.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
- Water consumption in the KBr group is significantly higher than that in the basal diet group at week 1-2, 7-8, 10, 13 and 24 in females.
OPHTHALMOSCOPIC EXAMINATION
- Ophtalmological examination revealed several lesions that were considered to be spontaneous in the KBr (500) and basal diet group at week 104. But there was no lesion that showed a significantly increased incidence in comparison with the basal diet group.
HAEMATOLOGY:
- There was no relevant difference between groups in haemotological indices. Males of the KBr (500) showed a slightly increased concentration n calcium at week 52 but the value was within the normal ranges of the historical data and there was no stastically difference between treated and control groups at week 104. Therefore, no toxicological significance is attached to this slight change seen at week 52. In addtion, a slight, but significant, decrease in blood urea nitrogen was seen in males of the KBr (500) group at week 52. Though such decrease is of no toxicological significance.
URINALYSIS:
- Urinalysis revealed significant increases in mean values of specific gravity and in the number of rats showing a moderate degree of urobilinogen at week 52 in comparison with basal diet group. However, these changes probably represent incidental findings with no toxicological significance, since the values of these parameters were within the normal range of the historical data. Moreover, this change are not found at week 104.
ORGAN WEIGHTS:
- No significance difference in the absolute weights of any organ in any treated groups in comparison with the basal diet group.
HISTOPATHOLOGY: NON-NEOPLASTIC:
- In the treated KBr group, the overall incidence of prostatitis (20/60) is significantly increased in comparison with the basal diet group (10/60). This lesion is described by the author as a focal inflammatory lesion characterised by neutrophilic infiltration into the glandular spaces, and had a morphological resemblance to the prostatic inflammation that occurs spontaneously in male F344 rats. There is no aggravation in the severity of prostatitis in the KBr (500) groups: the severity of the prostatitis in this group was very similar to that in the basl diet group. Therefore, the increased incidence of prostatitis is of no toxicological significance and is incidental.
HISTOPATHOLOGY: NEOPLASTIC:
- The incidence of mononuclear cell leukaemia in females of the KBr (500) group (11/60) was significantly higher than that in the basal diet group (4/60). Histopatologically, all tumours observed in this study were similar to those that are known to occur spontaneously in this strain of rats. Therefore it is concluded that the increase incidence of mononuclear cell leukaemia is not attributable to the treatment with KBr, but is fortuitus.
GROSS PATHOLOGY:
- No significance difference between treated and control groups - Dose descriptor:
- NOAEL
- Basis for effect level:
- other: see 'Remark'
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
- Conclusions:
- Rats received KBr in food for 104 weeks in a testing regime approximating OECD guideline 453. Animals were assessed regularly for signs of toxicity, and standard biochemical and urinalysis changes. Tissues were examined for tumour formation at interim, terminal sacrifice and when any other unplanned deaths occurred.
No detrimental changes were seen in the clinical signs, mortality, food and water consumption, ophthalmoscopic examination, haematology, clinical chemistry, urinalysis or organ weights of the treated animals.
Histologically, all tumours observed in this study were similar to those that are known to occur spontaneously in this strain of rats. Although the incidences of prostatitis (20/60) in males, and mononuclear cell leukaemia in treated females (11/60) were significantly increased, historical control data indicate that these increases were within the ranges of incidence previously observed for control animals at the testing laboratory and so neither increased incidence was considered to be treatment related.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Justification for classification or non-classification
Based on the conclusions from outlined above from subchronic toxicity studies and human dietary experience, it is considered unnecessary to conduct carcinogenicity studies or additional repeat dose toxicity studies.
Additional information
Rats received KBr in food for 104 weeks in a testing regime approximating OECD guideline 453.
No detrimental changes were seen in the clinical signs, mortality, food and water consumption, ophthalmoscopic examination, haematology, clinical chemistry, urinalysis or organ weights of the treated animals.
Histologically, all tumours observed in this study were similar to those that are known to occur spontaneously in this strain of rats. Although the incidences of prostatitis (20/60) in males, and mononuclear cell leukaemia in treated females (11/60) were significantly increased, historical control data indicate that these increases were within the ranges of incidence previously observed for control animals at the testing laboratory and so neither increased incidence was considered to be treatment related.
Sodium bromide is an inorganic salt that dissociates to its composite ions in aqueous solutions at environmental pH and temperature. Comparison of the available data on the various bromide salts have shown that the bromide ion is the relevant ion for determination of the toxicological profile with simple cations such as potassium, sodium or ammonium, that are ubiquitous in nature, having little or no influence on the bromide ion properties. It is therefore justified to read-across data from other inorganic bromide salts to sodium bromide.
The results from in vitro genotoxicity studies showed that sodium bromide was not genotoxic under the test conditions. Furthermore, the repeated dose studies did not show any evidence of cellular change, even in potential target tissues such as the endocrine (thyroid) or neural systems, that could be considered preneoplastic change (e.g. hyperplasia or metaplasia). No reports were found to indicate potential neoplastic change as a consequence of normal human exposure to bromide in the diet. Therapeutic exposure has not been associated with neoplastic change.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.